Clinical Trial

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 5, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is: • Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris. Participants will: * Take DHA every day for 3 months * Visit the clinic once every month for checkups and tests
Trial Details
NCT Number NCT07007078
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Acne Vulgaris
Enrollment 60 participants
Start Date 2025-06
Primary Completion 2026-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-05